-
Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis.
Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E.
Fetal Diagn Ther 2012;31:141-6. pdf -
Metabolomics and first-trimester prediction of early-onset preeclampsia.
Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K.
J Matern Fetal Neonatal Med 2012;25:1840-7. pdf -
Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis.
Roberge S, Giguère Y, Villa P, Nicolaides KH, Vainio M, Forest JC, von Dadelszen P, Vaiman D, Tapp S, Bujold E.
Am J Perinatol 2012;29:551-6. -
A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012;32:171-8. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012;31:42-8. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks.
Lefebvre J, Demers S, Bujold E, Nicolaides KH, Girard M, Brassard N, Audibert F.
Ultrasound Obstet Gynecol 2012;40:288-92. -
Maternal hemodynamics at 11-13 weeks' gestation and the risk of preeclampsia.
Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2012;40:28-34. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH.
Prenat Diagn 2000;20:411-6. -
Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia.
Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH.
BJOG 2000;107:795-7. -
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH.
BJOG 2000;107:1265-70. -
Increased fetal erythroblasts in women who subsequently develop pre-eclampsia.
Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH.
Hum Reprod 2000;15:1624-8. -
One-stage screening for pregnancy complications by color doppler assessment of the uterine arteries at 23 weeks' gestation.
Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH.
Obstet Gynecol 2000;96:559-64. -
Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation.
Snijders RJ, Sebire NJ, Nayar R, Souka A, Nicolaides KH.
Am J Med Genet 1999;86:205-7.